What changed: Renal cell carcinoma
Every dated change on the records linked to Renal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
Q2 2026 · 2
2026 · 6
- 2026ApprovalBelzutifanBelzutifan approved in US
Adjuvant clear-cell RCC with pembrolizumab
- 2026ApprovalPembrolizumabPembrolizumab approved in US
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
- 2026GuidelineRenal cell carcinomaGuideline NCCN Kidney v3.2026: Small renal mass (<4 cm)
Active surveillance, partial nephrectomy (usually robotic), or thermal ablation depending on growth, comorbidity, and biopsy; renal mass biopsy increasingly used. (NCCN 2A)
- 2026Trial resultLITESPARK-012LITESPARK-012 reported
Primary endpoint not met (ASCO GU 2026).
- 2026Trial resultLITESPARK-022LITESPARK-022 reported
DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).
- 2026MilestoneLITESPARK-022LITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls short
A milestone in how this cancer is treated.
2025 · 1
2024 · 2
December 2023 · 1
2023 · 5
- 2023ApprovalBelzutifanBelzutifan approved in US
Advanced RCC after PD-1/PD-L1 and VEGF-TKI
- 2023ApprovalVorolanibVorolanib approved in CN
Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)
- 2023Trial resultCONTACT-03CONTACT-03 reported
PFS HR 1.
- 2023Trial resultLITESPARK-005LITESPARK-005 reported
PFS HR 0.
- 2023MilestoneCOSMIC-313COSMIC-313 triplet fails on OS; CONTACT-03 closes IO rechallenge; belzutifan approved after IO/TKI (LITESPARK-005); ZIRCON validates CAIX PET
A milestone in how this cancer is treated.
2022 · 1
August 2021 · 1
2021 · 8
- 2021ApprovalBelzutifanBelzutifan approved in US
VHL-associated RCC, CNS haemangioblastoma, pNET
- 2021ApprovalCabozantinibCabozantinib approved in US
First-line advanced RCC with nivolumab (CheckMate 9ER)
- 2021ApprovalLenvatinibLenvatinib approved in US
Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab
- 2021ApprovalTivozanibTivozanib approved in US
Relapsed/refractory advanced RCC after ≥2 prior systemic therapies
- 2021Trial resultCLEAR (KEYNOTE-581)CLEAR (KEYNOTE-581) reported
PFS 23.
- 2021Trial resultKEYNOTE-564KEYNOTE-564 reported
DFS HR 0.
- 2021MilestoneBelzutifanBelzutifan approved
A milestone in how this cancer is treated.
- 2021MilestoneCheckMate 9ERNivolumab-cabozantinib, lenvatinib-pembrolizumab, adjuvant pembrolizumab, belzutifan (VHL), tivozanib approved
A milestone in how this cancer is treated.
2020 · 1
2019 · 3
April 2018 · 2
2018 · 3
- 2018Trial resultCheckMate 214CheckMate 214 reported
8-year OS HR 0.
- 2018MilestoneRenal cell carcinomaNivolumab-ipilimumab first line
A milestone in how this cancer is treated.
- 2018MilestoneCheckMate 214Nivolumab-ipilimumab first line (CheckMate 214); CARMENA questions cytoreductive nephrectomy
A milestone in how this cancer is treated.
2017 · 3
2016 · 3
2015 · 1
2014 · 1
2012 · 2
2009 · 3
2007 · 2
2006 · 3
2005 · 3
2001 · 1
1993 · 1
1992 · 3
- 1992ApprovalAldesleukin (high-dose IL-2)Aldesleukin (high-dose IL-2) approved in US
Metastatic renal cell carcinoma
- 1992MilestoneRenal cell carcinomaHigh-dose IL-2 approved
A milestone in how this cancer is treated.
- 1992MilestoneCytokines & engineered cytokinesHigh-dose IL-2 approved: first immunotherapy for RCC, with rare cures
A milestone in how this cancer is treated.